Palvella Therapeutics' Q1 net loss widens on higher costs

Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLA

0.00


Overview

  • US rare disease biopharma's Q1 net loss widened as R&D and admin costs increased

  • Company raised $230 mln in equity financing, ending Q1 with $261.9 mln in cash


Result Drivers

  • R&D SPENDING - Higher research and development expenses driven by increased manufacturing activities, headcount, and consulting services

  • ADMIN COSTS - General and administrative expenses rose due to increased headcount and professional services related to operating as a public company


Company press release: ID:nGNX8lydRj


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 EPS

-$1.20

Q1 Net Income

-$15.80 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Palvella Therapeutics Inc is $223.50, about 71.7% above its May 6 closing price of $130.17


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.